Page last updated: 2024-08-17

triiodothyronine and su 11248

triiodothyronine has been researched along with su 11248 in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's7 (87.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Alexandrescu, DT; Dasanu, CA; Dawson, N; Farzanmehr, H; Popoveniuc, G; Wartofsky, L1
Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B1
Danser, AH; de Krijger, RR; Eechoute, K; Kappers, MH; Leijten, F; Mathijssen, RH; Sleijfer, S; Smedts, FM; van den Meiracker, AH; van Esch, JH; Visser, TJ1
Braun, D; Hershman, JM; Kim, TD; Köhrle, J; le Coutre, P; Schweizer, U1
Hanovich, E; Hercbergs, AH; Kovel, S; Sella, A1
Atzori, F; Baghino, G; Boi, F; Ionta, MT; Mariotti, S; Pani, F; Tanca, L1

Reviews

1 review(s) available for triiodothyronine and su 11248

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

7 other study(ies) available for triiodothyronine and su 11248

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
    Thyroid : official journal of the American Thyroid Association, 2008, Volume: 18, Issue:7

    Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Thyroid Gland; Thyroiditis, Autoimmune; Thyrotropin; Thyroxine; Triiodothyronine

2008
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
    World journal of urology, 2011, Volume: 29, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine

2011
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:10

    Topics: Aged; Animals; Antineoplastic Agents; Body Weight; Capillaries; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Indoles; Iodide Peroxidase; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Rats; Rats, Inbred WKY; Regional Blood Flow; Regression Analysis; Retrospective Studies; Stomach Neoplasms; Sunitinib; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine

2011
Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:1

    Topics: Animals; Benzamides; Binding, Competitive; Biological Transport; Cells, Cultured; Clinical Trials as Topic; Dogs; Down-Regulation; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Indoles; Iodine Radioisotopes; Monocarboxylic Acid Transporters; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Symporters; Thyroxine; Transfection; Triiodothyronine

2012
Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
    Chemotherapy, 2012, Volume: 58, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Hypothyroidism; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Nephrectomy; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine

2012
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
    Thyroid : official journal of the American Thyroid Association, 2015, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Autoantibodies; Autoimmunity; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Thyroglobulin; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine

2015